Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
This product will be manufactured by Indoco at its manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa in India
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
The clinical trial will be conducted at 19 sites with 10,335 participants across India
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Subscribe To Our Newsletter & Stay Updated
